Aamodt R L, Rumble W F, Johnston G S, Foster D, Henkin R I
Am J Clin Nutr. 1979 Mar;32(3):559-69. doi: 10.1093/ajcn/32.3.559.
Seventeen patients were studied after separate oral and intravenous administration of 50 muCi Zn-69m to determine if Zn-69m is suitable for studying zinc metabolism in humans and to determine if the route of administration affects kinetics. Patients stayed on a metabolic ward for each study. Activity was measured in the total body, urine, feces, blood, plasma, red blood cells, and by detectors over liver and thigh. Five day urine to fecal ratios were 0.44 (intravenous), 0.018 (oral). Most activity went rapidly to liver, then followed two component exponential loss patterns in both cases. Thigh area doubling time was 5.7 days whether the zinc was given orally or intravenously. Plasma activity decreased to less than 2% of that injected by 24 hr after intravenous administration and decreased from a maximum of 1.2% of that ingested, 3 hr after oral administration to 0.7% by 24 hr. Red blood cell activity increased through the 5-day study period to maximum values of 6.4% of that injected after intravenous administration and 2.4% of that ingested after oral administration. Similar metabolic patterns were observed regardless of whether Zn-69m was administered intravenously or orally, suggesting that these patterns were not affected by the mode of administration for the cases studied.
对17名患者分别进行口服和静脉注射50微居里的锌-69m后进行研究，以确定锌-69m是否适合用于研究人体锌代谢，以及给药途径是否会影响动力学。每次研究时患者均住在代谢病房。对全身、尿液、粪便、血液、血浆、红细胞进行活性测量，并通过肝脏和大腿上方的探测器进行测量。5天的尿粪比分别为0.44（静脉注射）、0.018（口服）。大部分活性迅速进入肝脏，然后在两种情况下均呈现双指数衰减模式。无论锌是口服还是静脉注射，大腿部位的活性加倍时间均为5.7天。静脉注射后24小时，血浆活性降至注射量的2%以下，口服给药后3小时，血浆活性从摄入量的最高1.2%降至24小时后的0.7%。在为期5天的研究期间，红细胞活性增加，静脉注射后最高达到注射量的6.4%，口服给药后达到摄入量的2.4%。无论锌-69m是静脉注射还是口服，均观察到相似的代谢模式，这表明在所研究的病例中，这些模式不受给药方式的影响。
